Pharmocann teams with Shamir Institute on magic mushrooms

Publication Date08 November 2021
AuthorGlobes correspondent
The company will be 51% owned by Pharmocann and 49% owned by the Shamir Research Institute, which is based in Katzrin on the Golan Heights. The institute operates under the auspices of the University of Haifa, and has an international reputation in research on psilocybin mushrooms.

According to studies at leading universities, the use of psilocybin can benefit people suffering from depression, post traumatic demoralization syndrome, anxiety, and obsessive compulsive disorder.

Pharmocann has begun cultivating ten different strains of mushroom for the purposes of the research. After the active substances are extracted, it will be examined whether they can form a basis for the development of drugs for various medical indications, among them depression and Alzheimer's disease.

Under the agreement, which is not the first collaboration between the parties, Pharmocann will invest $110,000 for its stake in the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT